Clinical Trials Directory

We are doing this study to find out how changes in air pressure can affect people's exercise capacity. We want to compare how these pressure changes affect the abilities of healthy volunteers and compare their changes to those of people who are diagnosed with HFpEF (heart failure with a preserved ejection fraction, a congestive heart disease).

We are doing this study to support vaccine development by studying blood cells of the immune system.

We are doing this study to learn more about why the right side of the heart doesn't work well in certain heart conditions. We're using heart tissue samples from people with specific heart problems to help us make these important discoveries.

We are doing this study to collect blood and cerebrospinal fluid samples from patients who have breast cancer that has spread to the brain and/or spinal cord. We hope that by analyzing these samples, we can find out how effective different cancer medications are at treating metastases to the leptomeninges (tissue that surrounds the brain and spinal cord). We also want to do genetic testing on these samples to look for cancer mutations that can give us clues about how people might respond to different therapies or which therapies are most likely to be helpful.

We are doing this study to find the most effective, safe dose of an experimental drug called LNS8801 (the study drug) when it is given with or without pembrolizumab to people who have treatment-refractory unresectable melanoma.

We are doing this study to assess the long-term safety of an experimental drug called tegoprubart (the study drug) when it is given in combination with a standard immunosuppressive medicine, mycophenolate or mycophenolic acid, after a kidney transplant. The study will also look at the function and health of the implanted kidney and will assess how well the study drug can lower the risk of diabetes and transplant rejection.

We are doing this study to find out why some young adults have better lung function than others during the period of peak lung health (ages 25 to 35 years old) for most people. We want to learn how people's actions or exposures can affect lung function and risk of future lung disease. These factors might include smoking, vaping, or diet and environmental exposures to pollution and allergens.

We are doing this study to find out if an experimental drug called LY3962673 (the study drug) is a safe and effective option for cancer that has a KRAS G12D mutation. We are also trying to find the best dose level to use.